Opendata, web and dolomites


Liquid Foam Therapy (LIFT) for Acute Respiratory Distress Syndrome (ARDS)

Total Cost €


EC-Contrib. €






 LIFT project word cloud

Explore the words cloud of the LIFT project. It provides you a very rough idea of what is the project "LIFT" about.

newborn    vitro    optimize    sepsis    span    clinical    regions    nebulizers    demonstrated    administration    team    airway    drains    gravity    ards    babies    reduces    shift    inadequate    ex    surface    device    syndrome    age    advocate    depletion    lift    40    tension    hurdles    coating    care    lt    head    medicine    vivo    treatment    surfactant    therapeutic    srt    treat    business    brings    1ml    expand    patients    larger    distress    pig    copd    formulation    meanwhile    procedure    acute    hr    aerosols    instillations    run    people    carrier    pneumonia    inflammatory    133    inner    lung    printed    idiopathic    fluoroscopy    caused    rates    groups    mortality    models    distributes    drowning    leaving    feasibility    biomedical    paradigm    chest    obstructive    injury    homogeneously    foam    stem    life    overcome    bridges    chronic    disease    poc    doses    children    patent    leveraged    microfabricated    liquid    expertise    replacement    endotracheal    forces    annually    3d    small    animal    excised    experiments    pending    abundance    inhalation    fibrosis    100ml    saving    construct    therapy    therapies    cell    extend    respiratory    adults    pools    neonates    lungs    anesthetized    255    untreated    pulmonary    ipf    fail    broadly    lay    engineering    intensive   

Project "LIFT" data sheet

The following table provides information about the project.


Organization address
city: HAIFA
postcode: 32000

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 150˙000 €
 EC max contribution 150˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2018-PoC
 Funding Scheme ERC-POC
 Starting year 2018
 Duration (year-month-day) from 2018-10-01   to  2020-03-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 


 Project objective

Acute Respiratory Distress Syndrome (ARDS) is an inflammatory lung condition caused e.g. by sepsis, pneumonia and head or chest injury, affecting annually 133,000 people in Europe and 255,000 in the US. ARDS is characterized by the depletion of the lungs’ inner liquid coating (pulmonary surfactant), which reduces surface tension forces and allows the lungs to expand. Patients span across all age groups and lay anesthetized in the intensive care unit with mortality rates at 40%. Although surfactant replacement therapy (SRT) is a life-saving procedure in newborn neonates, current administration methods to treat adults and even children remain inadequate. Endotracheal surfactant liquid instillations used in babies fail in larger lungs: liquid drains into pools, drowning these lung regions while leaving others untreated. Meanwhile, inhalation aerosols can only deliver small doses (<1ml/hr for nebulizers), far from the required ~100ml of surfactant. To overcome such hurdles, we advocate using liquid foam as a surfactant carrier to the lungs, i.e. LIquid Foam Therapy (LIFT). Foam is weakly affected by gravity, distributes homogeneously within lungs and in abundance. LIFT brings a paradigm shift in SRT, and more broadly, in the field of therapeutic pulmonary delivery. Our team bridges expertise in clinical ARDS treatment in neonates, pulmonary medicine, biomedical engineering and business. Together, we have demonstrated the feasibility of our patent pending technology, both in vitro in 3D printed and microfabricated airway models, and ex vivo in excised pig lungs using fluoroscopy. In this PoC, we will optimize the foam formulation, design and construct a delivery device, and run pre-clinical in vivo animal experiments. LIFT has the potential to extend far beyond ARDS treatment and be leveraged for other lung therapies, such as stem cell delivery directly to the lungs to treat Idiopathic Pulmonary Fibrosis (IPF) and Chronic Obstructive Pulmonary Disease (COPD).

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LIFT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "LIFT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

NanoPD_P (2020)

High throughput multiplexed trace-analyte screening for diagnostics applications

Read More  

SPA4AstroQIT (2019)

Broadband Quantum-Limited Parametric Amplifier for Astronomy and Quantum Information Technology

Read More  

SuperH (2019)

Discovery and Characterization of Hydrogen-Based High-Temperature Superconductors

Read More  
lastchecktime (2022-12-09 5:06:43) correctly updated